TG li­cens­es Pre­ci­sion's cell ther­a­py; In­noven­t's PhI­II weight loss win; Atea's pos­i­tive hep C da­ta

Plus news about Eli­cio Ther­a­peu­tics, Boehringer In­gel­heim, Chiesi, Oak Hill Bio and Zealand Phar­ma:

TG Ther­a­peu­tics li­censed Pre­ci­sion Bio­Sciences’ cell ther­a­py for au­toim­mune dis­eases: TG will pay Pre­ci­sion $17.5 mil­lion in up­front and near-term mile­stones in a deal worth up to $288 mil­lion for glob­al rights to az­er-cel in au­toim­mune dis­eases and oth­er in­di­ca­tions out­side can­cer. Imu­gene holds the li­cense for az­er-cel in can­cer from a deal an­nounced in Au­gust. — Lei Lei Wu

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER